Safety profile of L-arginine infusion in moderately severe falciparum malaria.

dc.contributor.author

Yeo, Tsin W

dc.contributor.author

Lampah, Daniel A

dc.contributor.author

Gitawati, Retno

dc.contributor.author

Tjitra, Emiliana

dc.contributor.author

Kenangalem, Enny

dc.contributor.author

Granger, Donald L

dc.contributor.author

Weinberg, J Brice

dc.contributor.author

Lopansri, Bert K

dc.contributor.author

Price, Ric N

dc.contributor.author

Celermajer, David S

dc.contributor.author

Duffull, Stephen B

dc.contributor.author

Anstey, Nicholas M

dc.coverage.spatial

United States

dc.date.accessioned

2011-06-21T17:31:24Z

dc.date.issued

2008-06-11

dc.description.abstract

BACKGROUND: L-arginine infusion improves endothelial function in malaria but its safety profile has not been described in detail. We assessed clinical symptoms, hemodynamic status and biochemical parameters before and after a single L-arginine infusion in adults with moderately severe malaria. METHODOLOGY AND FINDINGS: In an ascending dose study, adjunctive intravenous L-arginine hydrochloride was infused over 30 minutes in doses of 3 g, 6 g and 12 g to three separate groups of 10 adults hospitalized with moderately severe Plasmodium falciparum malaria in addition to standard quinine therapy. Symptoms, vital signs and selected biochemical measurements were assessed before, during, and for 24 hours after infusion. No new or worsening symptoms developed apart from mild discomfort at the intravenous cannula site in two patients. There was a dose-response relationship between increasing mg/kg dose and the maximum decrease in systolic (rho = 0.463; Spearman's, p = 0.02) and diastolic blood pressure (r = 0.42; Pearson's, p = 0.02), and with the maximum increment in blood potassium (r = 0.70, p<0.001) and maximum decrement in bicarbonate concentrations (r = 0.53, p = 0.003) and pH (r = 0.48, p = 0.007). At the highest dose (12 g), changes in blood pressure and electrolytes were not clinically significant, with a mean maximum decrease in mean arterial blood pressure of 6 mmHg (range: 0-11; p<0.001), mean maximal increase in potassium of 0.5 mmol/L (range 0.2-0.7 mmol/L; p<0.001), and mean maximal decrease in bicarbonate of 3 mEq/L (range 1-7; p<0.01) without a significant change in pH. There was no significant dose-response relationship with blood phosphate, lactate, anion gap and glucose concentrations. All patients had an uncomplicated clinical recovery. CONCLUSIONS/SIGNIFICANCE: Infusion of up to 12 g of intravenous L-arginine hydrochloride over 30 minutes is well tolerated in adults with moderately severe malaria, with no clinically important changes in hemodynamic or biochemical status. Trials of adjunctive L-arginine can be extended to phase 2 studies in severe malaria. TRIAL REGISTRATION: ClinicalTrials.gov NCT00147368.

dc.description.version

Version of Record

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/18545693

dc.identifier.eissn

1932-6203

dc.identifier.uri

https://hdl.handle.net/10161/4494

dc.language

eng

dc.language.iso

en_US

dc.publisher

Public Library of Science (PLoS)

dc.relation.ispartof

PLoS One

dc.relation.isversionof

10.1371/journal.pone.0002347

dc.relation.journal

Plos One

dc.subject

Adult

dc.subject

Arginine

dc.subject

Blood Glucose

dc.subject

Blood Pressure

dc.subject

Dose-Response Relationship, Drug

dc.subject

Electrolytes

dc.subject

Humans

dc.subject

Hydrogen-Ion Concentration

dc.subject

Infusions, Intravenous

dc.subject

Malaria, Falciparum

dc.title

Safety profile of L-arginine infusion in moderately severe falciparum malaria.

dc.title.alternative
dc.type

Journal article

duke.contributor.orcid

Weinberg, J Brice|0000-0003-4052-5576

duke.date.pubdate

2008-6-11

duke.description.issue

6

duke.description.volume

3

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/18545693

pubs.begin-page

e2347

pubs.issue

6

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Global Health Institute

pubs.organisational-group

Immunology

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Hematology

pubs.organisational-group

Obstetrics and Gynecology

pubs.organisational-group

School of Medicine

pubs.organisational-group

University Institutes and Centers

pubs.publication-status

Published online

pubs.volume

3

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
263248800009.pdf
Size:
153.87 KB
Format:
Adobe Portable Document Format